Portfolio - Medical Devices


Daniel O'Mahony

PQ Bypass

PQBypass is developing new medical devices to treat peripheral vascular disease, by creating a minimally-invasive percutaneous surgical bypass.


PQ Bypass is a spin-out company from the Fogarty Institute for Innovation in Mtn. View, California, USA.

Our involvement:

Seroba co-led an investment of $15 million into PQ ByPass’s Series A in December 2012 as well as Series B in February 2016.  As a result of the Series A investment, PQ Bypass set up an Irish subsidiary.

Market Need:

Peripheral vascular disease affects up to 16% of the population 55 years and older, and is a known risk factor for coronary arterial disease, as well as myocardial infarction and ischemic stroke (American Hospital Association). It is estimated that only about a third of sufferers are diagnosed and treated, indicating the potential for further market growth.  The market for endovascular surgery and interventional approaches to treat peripheral occlusive disease is growing at a CAGR of 9% and is projected to have a value in excess of $5Bn by 2015.

Status: PQ Bypass is currently undertaking a CE Mark clinical study for its breakthrough, minimally-invasive technology to treat long lesions in the peripheral vasculature.  In addition, a clinical trial on its second portfolio product commenced in the first quarter of 2016.

< back to portfolio